1-乙基嘧啶-2,4(1H,3H)-二酮 | 6490-42-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 1-乙基嘧啶-2,4(1H,3H)-二酮
• 中文别名: 1-乙基嘧啶-2,4(1h,3H-)-二酮
• 英文名称: N-1-ethyluracil
• 英文别名: 1-ethyluracil；1-ethylpyrimidine-2,4(1H,3H)-dione；1-ethylpyrimidine-2,4-dione
• CAS: 6490-42-2
• 化学式: C₆H₈N₂O₂
• mdl: MFCD00136723
• 分子量: 140.142
• InChiKey: KPLDRYODCDLNHB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  49.4
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933599090
• 危险性防范说明：
  P261,P264,P271,P280,P302+P352,P304+P340,P305+P351+P338,P312,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H315,H319,H335

反应信息

• 作为反应物：
  描述：

  1-乙基嘧啶-2,4(1H,3H)-二酮 在 sodium azide 、 三氯氧磷 作用下， 以 乙腈 为溶剂， 反应 10.0h， 以94%的产率得到6-Ethyl-6H-tetrazolo[1,5-c]pyrimidin-5-one
  参考文献：
  名称：

  Ciszewski; Celewicz; Golankiewicz, Synthesis, 1995, # 7, p. 777 - 779

  摘要：

  DOI：
• 作为产物：
  描述：

  4-ethoxy-1-ethyl-2(1H)-pyrimidinone 在 盐酸 作用下， 生成 1-乙基嘧啶-2,4(1H,3H)-二酮
  参考文献：
  名称：

  Synthetic Nucleosides—Some 1-Glycosidouracils

  摘要：

  DOI：

  10.1021/ja01281a032

文献信息

• THIOARYL SUBSTITUTED INHIBITORS OF ZINC PROTEASES AND THEIR USE
  申请人：Rossello Armando

  公开号：US20090239829A1

  公开（公告）日：2009-09-24

  There are described compounds having the general formula (I) below and their pharmaceutically acceptable salts thereof, wherein E, X, m, q, R 1 , R 2 , n and ZBG have the meanings reported in the description useful, in therapy, as inhibitors of zinc metalloproteinases.

  描述了具有下面一般式（I）的化合物及其药学上可接受的盐，其中E、X、m、q、R1、R2、n和ZBG的含义如描述中所述，在治疗中作为锌金属蛋白酶的抑制剂。
• OLIGONUCLEOTIDE
  申请人：Kyowa Hakko Kirin Co., Ltd.

  公开号：US20150376611A1

  公开（公告）日：2015-12-31

  The present invention provides an oligonucleotide having improved affinity for AGO2, and the like. The oligonucleotide has a nucleotide residue or a nucleoside residue represented by formula (I) wherein X 1 is an oxygen atom or the like, R 1 is formula (IIA) (wherein R 5A is halogen or the like, and R 6A is a hydrogen atom or the like) or formula (IVA) (wherein Y 3A is a nitrogen atom or the like, and Y 4A is CH or the like), or the like, R 2 is a hydrogen atom, hydroxy, halogen, or optionally substituted lower alkoxy, and R 3 is a hydrogen atom or the like} at the 5′ end thereof, and the nucleotide residue or the nucleoside residue binds to an adjacent nucleotide residue through the oxygen atom at position 3.

  本发明提供了一种具有改善对AGO2亲和力的寡核苷酸等。该寡核苷酸在其5'端具有由式(I)表示的核苷酸残基或核苷酸残基其中X 1 是氧原子或类似物，R 1 是式(IIA)（其中R 5A 是卤素或类似物，而R 6A 是氢原子或类似物）或式(IVA)（其中Y 3A 是氮原子或类似物，而Y 4A 是CH或类似物），或类似物，R 2 是氢原子、羟基、卤素或可选择地取代的较低烷氧基，而R 3 是氢原子或类似物}，并且该核苷酸残基或核苷酸残基通过位于位置3的氧原子与相邻核苷酸残基结合。
• [EN] THIARABINE- AND THIARABINE PRODRUG-BASED TREATMENTS<br/>[FR] TRAITEMENTS À BASE DE PROMÉDICAMENT DE THIARABINE ET DE THIARABINE
  申请人：SOUTHERN RES INST

  公开号：WO2020247633A1

  公开（公告）日：2020-12-10

  The present disclosure is concerned with combination therapies that include sulfur- based nucleotide and nucleoside compounds for the treatment of various cancers such as, for example, sarcomas, carcinomas, hematological cancers, solid tumors, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, bladder cancer, thyroid cancer, testicular cancer, pancreatic cancer, endometrial cancer, melanomas, gliomas, leukemias, lymphomas, chronic myeloproliferative disorders, myelodysplastic syndromes, myeloproliferative neoplasms, and plasma cell neoplasms (myelomas). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  本公开涉及包括硫基核苷酸和核苷类化合物的联合疗法，用于治疗各种癌症，例如肉瘤、癌瘤、血液系统癌症、实体肿瘤、乳腺癌、宫颈癌、胃肠癌、结直肠癌、脑癌、皮肤癌、前列腺癌、卵巢癌、膀胱癌、甲状腺癌、睾丸癌、胰腺癌、子宫内膜癌、黑色素瘤、胶质瘤、白血病、淋巴瘤、慢性髓增生性疾病、骨髓增生异常综合征、髓增生性肿瘤和浆细胞肿瘤（骨髓瘤）等。本摘要旨在作为特定领域搜索的扫描工具，不旨在限制本发明。
• [EN] SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION<br/>[FR] PETITES MOLÉCULES DIRIGÉES CONTRE LE CÉRÉBLON POUR AMÉLIORER LA FONCTION DES LYMPHOCYTES T EFFECTEURS
  申请人：H LEE MOFFITT CANCER CENTER & RES INST INC

  公开号：WO2017161119A1

  公开（公告）日：2017-09-21

  Disclosed are small molecules against cereblon to enhance effector T cell function. Methodos of making thes molecules and methods of using them to treat various disease states are also disclosed.

  披露了针对小脑蛋白以增强效应T细胞功能的小分子。还披露了制造这些分子的方法以及使用它们治疗各种疾病状态的方法。
• Triphenylphosphine-free approach for one-pot N-alkylation of purine, pyrimidine, and azole derivatives with alcohols using P2O5/KI: A facile and selective route to access carboacyclic nucleosides
  作者：Somayeh Behrouz、Mohammad Navid Soltani Rad、Samira Ahmadi

  DOI：10.1016/j.tet.2019.130499

  日期：2019.9

  A facile, selective, and mild synthetic approach for one-pot N-alkylation of nucleobases and other related N-heterocycles via alcohols, using a mixture of P2O5 and KI is described. The reaction of structurally diverse purines, pyrimidines, and/or azoles with primary alcohols with the use of P2O5/KI and basic mixture of Et3N/K2CO3 in refluxing DMF affords the corresponding N-alkyl derivatives (carboacyclic

  描述了一种使用P 2 O 5和KI的混合物通过醇通过一锅法对核碱基和其他相关N-杂环进行N-烷基化的简便，选择性和温和的合成方法。使用P 2 O 5 / KI和Et 3 N / K 2 CO 3的碱性混合物，使结构不同的嘌呤，嘧啶和/或唑与伯醇反应在回流中，DMF以良好至合理的产率得到相应的N-烷基衍生物（碳环核苷）。评估了包括溶剂，碱，温度和底物/试剂比率的不同参数对反应进程的影响。仲和叔醇不能与核碱基反应。当前方案的主要优点是形成水溶性副产物，其中提供了简单的后处理和纯化过程。